Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that contains an exogenous Clostridial toxin substrate which comprises a fluorescent member, a membrane targeting domain and a Clostridial toxin recognition sequence comprising a cleavage site, where the cleavage site intervenes between the fluorescent member and the membrane targeting domain; and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
Type:
Grant
Filed:
April 4, 2006
Date of Patent:
November 29, 2011
Assignee:
Allergan, Inc.
Inventors:
Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Type:
Grant
Filed:
October 27, 2007
Date of Patent:
November 22, 2011
Assignee:
The Regents of the University of Colorado
Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
Type:
Grant
Filed:
April 24, 2007
Date of Patent:
November 15, 2011
Assignee:
Cubist Pharmaceuticals, Inc.
Inventors:
Thomas Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul Lynch, Maurizio Zenoni, Auro Tagliani
Abstract: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
November 8, 2011
Assignee:
Novo Nordisk Health Care A/G
Inventors:
Niels Kristian Klausen, Soren Bjorn, Carsten Behrens, Patrick William Garibay
Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
Type:
Grant
Filed:
March 24, 2008
Date of Patent:
November 1, 2011
Assignee:
HDL Therapeutics
Inventors:
Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
Abstract: The invention relates to an osteogenic composite matrix consisting of collagen and non-collagen components of an extracellular matrix (ECM-components), to a method for producing said matrix, to a method for producing an implant or a scaffold for tissue engineering which is provided with a coating formed by said osteogenic composite matrix and is used for stimulating and accelerating a hard tissue formation such as, for example. The implant osseointegration in bones. The inventive osteogenic composite matrix comprises a collagen and at least one non-collagen ECM component or the derivatives thereof, wherein the collagen component consists of non-crosslinked collagen fibers produced by fibrillogenesis and the non-collagen ECM component or the derivatives thereof are integrated into said collagen fibers.
Abstract: The invention provides a method of monitoring the response of platelets to a COX1 inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX 1 inhibitor; mixing the blood with a COX 1-dependent platelet agonist, such as arachidonic acid, monitoring extracellular ATP in the agonist-activated blood to generate a measurement, and comparing the measurement to a standard value. Devices, systems, and kits for carrying out the method are also provided.
Abstract: The invention provides nitrilases and methods for making and using them, and in one aspect, provides methods for producing enantiomerically pure ?-substituted carboxylic acids, such as, for example, ?-amino acids and ?-hydroxy acids. In one aspect, methods of the invention combine an aldehyde or ketone with a cyanide and ammonia or an ammonium salt or an amine, in the presence of a nitrilase or a polypeptide having nitrilase activity, to stereoselectively hydrolyze the amino nitrile or cyanohydrin intermediate under conditions sufficient to produce the carboxylic acid.
Type:
Grant
Filed:
October 8, 2007
Date of Patent:
October 11, 2011
Assignee:
Verenium Corporation
Inventors:
Mark Madden, David Weiner, Jennifer Ann Chaplin
Abstract: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.
Abstract: The ionic conjugates include an inorganic particle electrostatically associated with a macromolecule which can interact specifically with predetermined chemical species or biological targets.
Type:
Grant
Filed:
December 19, 2008
Date of Patent:
October 11, 2011
Assignee:
Massachusetts Institute of Technology
Inventors:
George P. Anderson, Hedi Mattoussi, J. Matthew Mauro, Moungi G. Bawendi, Vikram C. Sundar
Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
Type:
Grant
Filed:
March 5, 2008
Date of Patent:
October 4, 2011
Assignee:
HDL Therapeutics
Inventors:
Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
Abstract: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.
Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.
Type:
Grant
Filed:
November 12, 2009
Date of Patent:
September 27, 2011
Assignee:
Novo Nordisk Health Care AG
Inventors:
Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.
Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
Type:
Grant
Filed:
August 15, 2008
Date of Patent:
September 20, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
Abstract: The present invention is a method for preparing a hemoglobin based oxygen carrier to deliver oxygen to tissue. The method comprises mixing a deoxygenated hemoglobin with a maleimide-activated polyakylene oxide (PAO) to obtain an oxygen carrying product. This product is characterized as having 2 to about 8 PAO moieties covalently bound to a deoxygenated hemoglobin and a p50 less than native stroma-free hemoglobin from the same animal source when measured under the same conditions.
Type:
Grant
Filed:
August 6, 2009
Date of Patent:
September 20, 2011
Assignee:
Sangart, Inc.
Inventors:
Kim D. Vandegriff, Ashok S. Malavalli, Gnel M. Mkrtchyan
Abstract: The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections.
Abstract: A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop sequence. The HBc chimer preferably contains an influenza-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimers are also disclosed.
Abstract: Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.
Abstract: A colorimetric and/or fluorescent detector, which comprises a film of polydiacetylenes and lipids deposited on a substrate, wherein said film is coated with one or more layers, wherein at least one of said layers is capable of supporting the growth of microorganisms. Also provided are processes for preparing the novel colorimetric and/or fluorescent detector and uses thereof in the detection of bacteria.